Compare Cytokinetics Inc (CYTK) vs Paychex, Inc. (PAYX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Paychex, Inc. — how do they compare? Cytokinetics Inc trades at $76.44 (market cap $10.63B), while Paychex, Inc. trades at $119.35 (market cap $43.14B). The key difference: Paychex, Inc. is far larger — about 4.1× Cytokinetics Inc's market cap, and Paychex, Inc. pays a 3.92% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | PAYX | |
|---|---|---|
Market Cap | $10.63B | $43.14B |
Sector | Technology | Industrials |
52-Week High | $87.26 | $140.81 |
52-Week Low | $34.31 | $85.57 |
Enterprise Value | $10.74B | $46.63B |
Dividend Yield | — | 3.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
Paychex (PAYX) trades at $121.18, up 0.95% with a bullish technical outlook and strong fundamentals. The company maintains robust profitability with 27.03% net margins and consistent earnings beats. Recent expansion of WISE platform and steady small business employment trends support growth. Technical indicators show bullish momentum with support at $120 and resistance at $122.
PAYX offers stable dividend income and consistent execution but faces valuation concerns with P/E of 24.81 above sector averages. Analyst consensus remains cautious with 63% hold ratings. Key risks include economic sensitivity and competitive pressures in HR services. Upside depends on continued market share gains and margin maintenance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →
